These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 33207902)

  • 1. Effectiveness and safety of switching to adalimumab biosimilar ABP 501 in Crohn's disease.
    Viscido A; Latella G
    Rev Esp Enferm Dig; 2021 Feb; 113(2):154-155. PubMed ID: 33207902
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness and safety of switching to adalimumab biosimilar ABP 501 in Crohn's disease: the extrapolation concept.
    Ribaldone DG; Vernero M; Astegiano M
    Rev Esp Enferm Dig; 2021 Feb; 113(2):155. PubMed ID: 33207912
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness and safety of adalimumab biosimilar ABP 501 in Crohn's disease: an observational study.
    Ribaldone DG; Caviglia GP; Pellicano R; Vernero M; Saracco GM; Morino M; Astegiano M
    Rev Esp Enferm Dig; 2020 Mar; 112(3):195-200. PubMed ID: 32054272
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SPOSAB ABP 501: A Sicilian Prospective Observational Study of Patients with Inflammatory Bowel Disease Treated with Adalimumab Biosimilar ABP 501.
    Macaluso FS; Cappello M; Busacca A; Fries W; Viola A; Costantino G; Magnano A; Vinci E; Ferracane C; Privitera AC; Piccillo G; Belluardo N; Giangreco E; Romano C; Citrano M; Graziano F; Garufi S; Bertolami C; Ventimiglia M; Scrivo B; Teresi G; Renna S; Rizzuto G; Casà A; Orlando A;
    J Gastroenterol Hepatol; 2021 Nov; 36(11):3041-3049. PubMed ID: 34152636
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A switch from originator-adalimumab to the biosimilar SB5 in patients with Crohn's disease: an analysis of two propensity score-matched cohorts.
    Lukas M; Kolar M; Reissigova J; Duricova D; Machkova N; Hruba V; Lukas M; Vasatko M; Jirsa J; Pudilova K; Malickova K
    Scand J Gastroenterol; 2022 Jul; 57(7):814-824. PubMed ID: 35234552
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Switching From Originator Adalimumab to the Biosimilar SB5 in Patients With Inflammatory Bowel Disease: Short-term Experience From a Single Tertiary Clinical Centre.
    Lukas M; Malickova K; Kolar M; Bortlik M; Vasatko M; Machkova N; Hruba V; Duricova D; Lukas M
    J Crohns Colitis; 2020 Jul; 14(7):915-919. PubMed ID: 31905382
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Switching from Biosimilar to Biosimilar Adalimumab, Including Multiple Switching, in Crohn's Disease: A Prospective Study.
    Ribaldone DG; Tribocco E; Rosso C; Armandi A; Vernero M; Bugianesi E; Astegiano M; Saracco GM; Caviglia GP
    J Clin Med; 2021 Jul; 10(15):. PubMed ID: 34362184
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-World Experience of Adalimumab Biosimilar (ABP 501) Use in Patients with Inflammatory Bowel Disease in Europe.
    Jin R; Nduka C; Courmier D; Knight H; Meadows R; Piercy J; Cummings JRF; Radziszewski W
    Adv Ther; 2024 Jan; 41(1):331-348. PubMed ID: 37957522
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy, tolerability, and safety of infliximab biosimilar in comparison to originator biologic and adalimumab in patients with Crohn disease.
    Kaniewska M; Rosołowski M; Rydzewska G
    Pol Arch Intern Med; 2019 Aug; 129(7-8):484-489. PubMed ID: 31316042
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SB5: An Adalimumab Biosimilar.
    Frampton JE
    BioDrugs; 2018 Oct; 32(5):507-510. PubMed ID: 30251234
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A single-centre, observational, retrospective, real-life study evaluating adalimumab biosimilar ABP 501 in the treatment of plaque-type psoriasis and psoriatic arthritis in originator-naïve patients and in patients undergoing non-medical switch from originator.
    Giunta A; Zangrilli A; Bavetta M; Manfreda V; Pensa C; Bianchi L
    Curr Med Res Opin; 2021 Jul; 37(7):1099-1102. PubMed ID: 34011212
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness and safety of adalimumab biosimilar in patients with inflammatory bowel disease.
    Poquet-Jornet JE; Ibáñez-Sala I; Garrigues-Pelufo T; Munilla-Das A; Valdivia-Pérez A; Carrera-Hueso FJ
    Farm Hosp; 2024 Apr; ():. PubMed ID: 38570210
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum concentrations after switching from originator infliximab to the biosimilar CT-P13 in patients with quiescent inflammatory bowel disease (SECURE): an open-label, multicentre, phase 4 non-inferiority trial.
    Strik AS; van de Vrie W; Bloemsaat-Minekus JPJ; Nurmohamed M; Bossuyt PJJ; Bodelier A; Rispens T; van Megen YJB; D'Haens GR;
    Lancet Gastroenterol Hepatol; 2018 Jun; 3(6):404-412. PubMed ID: 29606564
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical experience with adalimumab biosimilar imraldi in hidradenitis suppurativa.
    Ricceri F; Rosi E; Di Cesare A; Pescitelli L; Fastame MT; Prignano F
    Dermatol Ther; 2020 Nov; 33(6):e14387. PubMed ID: 33030281
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ABP 501 (adalimumab-atto) in the treatment of inflammatory bowel disease: an example of evidence-based extrapolation.
    Muñoz Núñez F; Taxonera C; Marrón J
    Rev Esp Enferm Dig; 2021 Oct; 113(10):737-738. PubMed ID: 33648343
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adalimumab biosimilars in the therapy of Crohn´s disease and ulcerative colitis: Prospective multicentric clinical monitoring.
    Wasserbauer M; Hlava S; Drabek J; Stovicek J; Minarikova P; Nedbalova L; Drasar T; Zadorova Z; Dolina J; Konecny S; Kojecky V; Kozeluhova J; Cernikova P; Pichlerova D; Kucerova B; Coufal S; Keil R
    PLoS One; 2022; 17(8):e0271299. PubMed ID: 35939424
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of biosimilar CT-P13 compared with originator infliximab in patients with active Crohn's disease: an international, randomised, double-blind, phase 3 non-inferiority study.
    Ye BD; Pesegova M; Alexeeva O; Osipenko M; Lahat A; Dorofeyev A; Fishman S; Levchenko O; Cheon JH; Scribano ML; Mateescu RB; Lee KM; Eun CS; Lee SJ; Lee SY; Kim H; Schreiber S; Fowler H; Cheung R; Kim YH
    Lancet; 2019 Apr; 393(10182):1699-1707. PubMed ID: 30929895
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness and safety of switching from originator to biosimilar adalimumab in patients with psoriasis.
    Nielsen VW; Lund TT; Gniadecki R; Olsen RH; Nissen CV; Schwensen JFB; Thomsen SF
    Dermatol Ther; 2020 Nov; 33(6):e14258. PubMed ID: 32865289
    [No Abstract]   [Full Text] [Related]  

  • 19. Review of Biosimilar Trials and Data on Adalimumab in Rheumatoid Arthritis.
    Zhao S; Chadwick L; Mysler E; Moots RJ
    Curr Rheumatol Rep; 2018 Aug; 20(10):57. PubMed ID: 30094742
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical similarity of the biosimilar ABP 501 compared with adalimumab after single transition: long-term results from a randomized controlled, double-blind, 52-week, phase III trial in patients with moderate-to-severe plaque psoriasis.
    Papp K; Bachelez H; Costanzo A; Foley P; Gooderham M; Kaur P; Philipp S; Spelman L; Zhang N; Strober B
    Br J Dermatol; 2017 Dec; 177(6):1562-1574. PubMed ID: 28755394
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.